Search hospitals > Ontario > TORONTO
University Health Network
Claim this profileTORONTO, Ontario M5G 2C4
Global Leader in Cancer
Global Leader in Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Infections
Conducts research for COVID-19
541 reported clinical trials
60 medical researchers
Summary
University Health Network is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Prostate Cancer, Lung Cancer, Infections, COVID-19 and other specialties. University Health Network is involved with conducting 541 clinical trials across 579 conditions. There are 60 research doctors associated with this hospital, such as Lillian Siu, MD, Marcus Butler, Anna Spreafico, MD PhD, and John Kuruvilla, MD.Area of expertise
1Cancer
Global LeaderStage IV
TP53 positive
HER2 positive
2Prostate Cancer
Global LeaderStage IV
Top PIs
Lillian Siu, MDPrincess Margaret Cancer Centre7 years of reported clinical research
Studies Cancer
Studies Breast Cancer
16 reported clinical trials
39 drugs studied
Marcus ButlerPrincess Margaret Cancer Centre7 years of reported clinical research
Studies Melanoma
Studies Bladder Cancer
13 reported clinical trials
24 drugs studied
Anna Spreafico, MD PhDPrincess Margaret Cancer Centre6 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
11 reported clinical trials
23 drugs studied
John Kuruvilla, MDPrincess Margaret Cancer Centre8 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
7 reported clinical trials
17 drugs studied
Clinical Trials running at University Health Network
Cancer
Breast Cancer
Prostate Cancer
Brain Tumor
Stroke
Bladder Cancer
Lymphoma
Acute Leukemia
Non-Small Cell Lung Cancer
Depression
Stopping Heart Medications
for Cancer Survivors
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in >80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 and 9 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
Recruiting3 awards Phase 4
IVLP with Oxaliplatin
for Colorectal Cancer Spread to Lungs
This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP technique has been used recently in a Phase I study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. The purpose of this study is to test the safety of the IVLP technique and find the dose that seems right in humans. Participants are given oxaliplatin into one lung via IVLP and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. Participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.
Recruiting1 award Phase 1
Early Detection Test
for Cancer
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of the GRAIL MCED test in a population of individuals who are eligible for guideline-recommended cancer screening. In cases with a "cancer signal detected" test result, participants will undergo diagnostic procedures based on the test returned cancer signal origin(s) to determine if they have cancer. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. The study will enroll approximately 35,000 and no more than 38,500 participants as defined by eligibility criteria over an anticipated enrollment period of approximately 36 months at up to 40 clinical institutions within North America. Participants will be actively followed for approximately 3 years from the date of their enrollment.
Recruiting1 award N/A2 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Health Network?
University Health Network is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Prostate Cancer, Lung Cancer, Infections, COVID-19 and other specialties. University Health Network is involved with conducting 541 clinical trials across 579 conditions. There are 60 research doctors associated with this hospital, such as Lillian Siu, MD, Marcus Butler, Anna Spreafico, MD PhD, and John Kuruvilla, MD.
Where is University Health Network located?
**University Health Network Hospital Location and Access:**
- **Address:** 200 Elizabeth St, Downtown Toronto, ON. Located near the intersection of College Street and University Avenue.
- **Public Transportation:** Accessible via Queen's Park subway station on Line 1 (Yonge-University-Spadina line), 506 Carlton, and 505 Dundas streetcars.
- **Parking:** Available at the hospital. Note: Street parking is restricted.
Who should I call to ask about financial aid or insurance network?
For financial assistance at University Health Network:
- Contact by phone: 888.531.3004 (Monday-Friday, 8am - 4:30pm) or use the online form.
- For insurance inquiries: Call 210-358-3350 or use the Contact Us form. Verify insurance acceptance with your provider.
- Billing support: Call 210-358-3260.
- Apply for financial assistance through the University Health Financial Assistance Program, considering residency, income, and family size.
What insurance does University Health Network accept?
The University Health Network (UHN) accepts a wide range of insurance plans, including Medicare, Medicaid/Health First CO, and many others, and strives to be in-network for most insurance plans. However, patients are advised to confirm network status and coverage details with their insurance provider and clinic before receiving services. Similarly, CU Medicine and University Hospitals Lake West Medical Center accept most major insurance plans, but it is crucial for patients to verify specific provider participation and in-network status with their insurance carrier prior to their visit to avoid unexpected out-of-pocket expenses.
What awards or recognition has University Health Network received?
University Health Network (UHN) in Toronto, Ontario, Canada, specializes in health research and patient care across various domains including cancer, cardiovascular sciences, and transplantation. Affiliated with the University of Toronto, UHN is a key player in the Toronto Academic Health Science Network, emphasizing innovation in medical research and education. Its renowned research institutes, such as the Krembil Research Institute and the Princess Margaret Cancer Centre, are internationally recognized for their medical contributions.